Join us for an expert-led session exploring the rising concern of measles outbreaks and their unique risks for patients undergoing Hematopoietic Cell Transplantation (HCT) and CAR T-cell therapies.
Join ASTCT Director of Government Relations, Alycia Maloney, JD, and the reimbursement and policy advisors to ASTCT from Nimitt Consulting, for the Medicare FY 2026 IPPS Proposed...
Scientists are learning more about how T cell trogocytosis — the exchange of membrane-associated proteins between cells — is regulated, knowledge that could potentially unlock novel...
During the webinar, Drs. White and Nezalova-Henriksen will present two articles related to: (a) Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic HSCT for older...
by Nature Medicine
Developers are encouraged by the robust anti-tumor potency demonstrated by their novel chimeric receptor, the Dual-targeting Synthetic TCR and Antigen Receptor (D-STAR).
by Nature Medicine
Despite ongoing concerns, results from a French database study characterize the risk of secondary cancers after chimeric antigen receptor (CAR) T-cell therapy as very low.